Novo Nordisk (CPSE:NOVO B) Wins EU Oral Wegovy Approval, Where Does Fair Value Sit?
Novo Nordisk (CPSE:NOVO B) is back in focus after European regulators cleared its once daily Wegovy pill, and Crux announced a US employer-focused collaboration to widen access to its anti obesity medications.
See our latest analysis for Novo Nordisk.
These Wegovy updates have landed while Novo Nordisk’s stock has shown strong recent momentum, with a 90 day share price return of 23.14% but a weaker 1 year total shareholder return, which is down 24.28%.
If this obesity and diabetes story has your attention, it could be a good moment to widen your research using our screener for other healthcare focused AI opportunities like 129 healthcare AI stocks
The recent surge in Novo Nordisk, set against a 1 year total return that is still in decline and a market price now sitting above the average analyst target but far below some intrinsic estimates, raises a simple issue: where does fair value really sit?
Most Popular Narrative: 13.8% Overvalued
Novo Nordisk last closed at DKK326.5 against a narrative fair value of DKK287, which frames the current price as rich relative to that narrative anchor.
Novo Nordisk’s business model is straightforward. It develops hormone-based therapies, protects them with patents, manufactures them at scale, and sells them at high margins into reimbursed healthcare systems. In obesity, GLP-1 drugs such as Wegovy transformed the company into a perceived structural growth leader. The stock was priced for durable dominance. The pullback reflects emerging limits to that assumption.
Want to see what sits behind that verdict on Wegovy and obesity growth assumptions? The key levers are GLP-1 penetration, pricing power, and long run margins.
According to ctmlin910, the narrative leans heavily on how much of the theoretical GLP-1 opportunity Novo Nordisk can capture, what level of reimbursement sticks, and what sort of earnings multiple investors are willing to assign if those conditions hold or soften over time. The fair value of DKK287 is built around those moving parts rather than short term price swings.
Result: Fair Value of DKK287 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Novo Nordisk’s narrative could shift quickly if GLP-1 reimbursement widens meaningfully or if capacity constraints ease faster than expected, which could alter perceived limits on obesity revenue.
Find out about the key risks to this Novo Nordisk narrative.
Another View: Multiples Point to Novo Nordisk as Cheap
The user narrative pegs Novo Nordisk as 13.8% overvalued at DKK287, but current market data tells a different story. On 11.8x P/E, the stock trades well below the European pharmaceuticals average of 21.3x, the peer average of 24.7x, and an estimated fair ratio of 22.9x. If the market ever moved closer to that fair ratio, today’s pricing could look very different. Which version of fair value do you trust more: the story, or the simple multiple check?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Novo Nordisk pulling investors in different directions, why wait on consensus when you can weigh the trade off between concerns and optimism yourself using 3 key rewards and 4 important warning signs
Looking for more ideas beyond Novo Nordisk?
If Novo Nordisk has sharpened your focus on quality research, do not stop here. The next opportunity you miss could be the one that changes your portfolio.
- Target potential mispricings by scanning companies that combine quality fundamentals with attractive pricing through the 250 high quality undervalued stocks.
- Strengthen your income stream by reviewing resilient payers in the 456 dividend fortresses to see which yields might fit your goals.
- Prioritise resilience by checking companies with steadier profiles using the 303 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com